$BSU
BSU
Alpha
0.12074
-0.30%
Eli Lilly's Q4 2025 results confirm a massive 43% revenue surge to $19.3 billion, $GWEI
GWEIUSDT
Perp
0.028415
+12.13%
fueled by explosive volume growth in Mounjaro and Zepbound. Both exceeded analyst estimates, as did the **$7.54 adjusted EPS**. The optimistic 2026 revenue guidance ($80B–$83B) reflects sustained global demand for its GLP-1 therapies, solidifying Lilly's market leadership in weight-loss medicine.